New Insights into Diagnosing Subtle Focal Cortical Dysplasia with MR Fingerprinting

For clinicians managing medically refractory focal epilepsy, a significant challenge often lies in interpreting brain MRI scans that appear normal. Subtle focal cortical dysplasia (FCD) can be difficult to visualize on standard MRI, potentially delaying or leading to unsuccessful epilepsy surgeries. However, recent advancements in magnetic resonance fingerprinting (MRF) – a rapid, quantitative imaging technique – are improving the detection of these elusive lesions and helping to identify those actively driving a patient’s seizures.

Understanding Focal Cortical Dysplasia

Focal cortical dysplasia (FCD) is a neurological disorder characterized by disruptions in the localized organization and development of brain cells [1]. It is strongly associated with drug-resistant epilepsy, particularly in children and young adults [1]. FCD affects the cerebral cortex, the outermost layer of the brain responsible for movement, thought, speech, memory, intelligence and personality [1]. The condition involves the development of incorrectly formed cells in the cerebral cortex before birth [1].

The Promise of Magnetic Resonance Fingerprinting (MRF)

Two recent studies from the Cleveland Clinic demonstrate the potential of MRF to significantly enhance the detection of subtle FCD lesions. MRF is a rapid imaging technique that generates T1 and T2 maps of the brain, providing quantitative data that can be analyzed using machine learning.

Study 1: Automated Detection and Subtyping

Researchers developed a framework for whole-brain FCD detection by combining MRF with machine learning and surface-based morphometry [1]. The study analyzed 44 patients with confirmed FCD and 70 healthy controls. Key findings included:

• Enhanced Sensitivity: Combining T1-weighted images with MRF and FLAIR resulted in 71.4% sensitivity for FCD detection, compared to 57% detected by clinical MRI alone.
• Reduced False Positives: MRF data significantly reduced false-positive clusters in both patients and controls.
• Accurate Subtyping: The framework accurately distinguished between type II FCD and other malformations with 80.8% accuracy.
• Interpretability: Probability values generated by the framework may serve as a confidence measure for lesion detection.
• Prognostic Value: The framework showed higher sensitivity for FCD detection in patients who became seizure-free after surgery (72.7%) compared to those who did not (50.0%).

Study 2: Differentiating Epileptogenic Lesions

The second study investigated whether MRF could differentiate between epileptogenic (seizure-causing) and silent malformations in patients with multiple cortical abnormalities [1]. Analysis of 69 individuals, including 21 with refractory focal epilepsy, revealed that:

• Gray Matter T1 as a Signature: Epileptogenic malformations consistently showed higher gray matter T1 values compared to non-epileptogenic regions.
• Unmasking MRI-Negative Foci: In one case, MRF detected an elevated T1 and T2 signal in a region that appeared normal on conventional MRI, which was later confirmed by SEEG as the seizure onset zone.

Implications for Clinical Practice

These studies suggest that MRF offers several benefits for the management of intractable epilepsy:

• It provides value beyond visual detection, characterizing tissue pathology and aiding in the diagnosis of MRI-negative cases.
• It can help optimize stereoelectroencephalography (SEEG) implantation by guiding electrode placement based on T1 values.
• It has the potential to reduce false positives in automated lesion detection.
• It may offer noninvasive biomarkers for predicting seizure outcomes.

As MRF becomes more widely validated and accessible, it has the potential to grow an integral part of the presurgical evaluation and surgical planning process for patients with refractory focal epilepsy.